Vectormune ND

Country: European Union

Language: German

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

zellassoziiertes lebendes rekombinantes Putenherpesvirus (rHVT / ND), das das Fusionsprotein des lentogenen Stammes des Newcastle diseases virus D-26 exprimiert

Available from:

CEVA-Phylaxia Co. Ltd.

ATC code:

QI01AD

INN (International Name):

Newcastle disease and Marek’s disease vaccine (live recombinant)

Therapeutic group:

Chicken; Embryonated eggs

Therapeutic area:

Immunologischen Arzneimitteln für aves, Live virale Impfstoffe

Therapeutic indications:

Für die aktive Immunisierung von 18 Tage alten embryonated chicken eggs oder ein-Tag-alte Küken zu verringern, die Sterblichkeit und die klinischen Anzeichen verursacht durch Newcastle disease virus und zur Verringerung der Mortalität, der klinischen Anzeichen und Läsionen, verursacht durch Marek ' s disease virus mit einem Phänotyp "virulent".

Product summary:

Revision: 7

Authorization status:

Autorisiert

Authorization date:

2015-09-08

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Aktuelle Informationen zu diesem Tierarzneimittel finden Sie auf der
Website mit Informationen über
Tierarzneimittel.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Aktuelle Informationen zu diesem Tierarzneimittel finden Sie auf der
Website mit Informationen über
Tierarzneimittel.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-02-2024
Public Assessment Report Public Assessment Report Bulgarian 10-04-2018
Patient Information leaflet Patient Information leaflet Spanish 15-02-2024
Public Assessment Report Public Assessment Report Spanish 10-04-2018
Patient Information leaflet Patient Information leaflet Czech 15-02-2024
Public Assessment Report Public Assessment Report Czech 10-04-2018
Patient Information leaflet Patient Information leaflet Danish 15-02-2024
Public Assessment Report Public Assessment Report Danish 10-04-2018
Patient Information leaflet Patient Information leaflet Estonian 15-02-2024
Public Assessment Report Public Assessment Report Estonian 10-04-2018
Patient Information leaflet Patient Information leaflet Greek 15-02-2024
Public Assessment Report Public Assessment Report Greek 10-04-2018
Patient Information leaflet Patient Information leaflet English 15-02-2024
Public Assessment Report Public Assessment Report English 10-04-2018
Patient Information leaflet Patient Information leaflet French 15-02-2024
Public Assessment Report Public Assessment Report French 10-04-2018
Patient Information leaflet Patient Information leaflet Italian 15-02-2024
Public Assessment Report Public Assessment Report Italian 10-04-2018
Patient Information leaflet Patient Information leaflet Latvian 15-02-2024
Public Assessment Report Public Assessment Report Latvian 10-04-2018
Patient Information leaflet Patient Information leaflet Lithuanian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-02-2024
Public Assessment Report Public Assessment Report Lithuanian 10-04-2018
Patient Information leaflet Patient Information leaflet Hungarian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 15-02-2024
Public Assessment Report Public Assessment Report Hungarian 10-04-2018
Patient Information leaflet Patient Information leaflet Maltese 15-02-2024
Public Assessment Report Public Assessment Report Maltese 10-04-2018
Patient Information leaflet Patient Information leaflet Dutch 15-02-2024
Public Assessment Report Public Assessment Report Dutch 10-04-2018
Patient Information leaflet Patient Information leaflet Polish 15-02-2024
Public Assessment Report Public Assessment Report Polish 10-04-2018
Patient Information leaflet Patient Information leaflet Portuguese 15-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 15-02-2024
Public Assessment Report Public Assessment Report Portuguese 10-04-2018
Patient Information leaflet Patient Information leaflet Romanian 15-02-2024
Public Assessment Report Public Assessment Report Romanian 10-04-2018
Patient Information leaflet Patient Information leaflet Slovak 15-02-2024
Public Assessment Report Public Assessment Report Slovak 10-04-2018
Patient Information leaflet Patient Information leaflet Slovenian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 15-02-2024
Public Assessment Report Public Assessment Report Slovenian 10-04-2018
Patient Information leaflet Patient Information leaflet Finnish 15-02-2024
Public Assessment Report Public Assessment Report Finnish 10-04-2018
Patient Information leaflet Patient Information leaflet Swedish 15-02-2024
Public Assessment Report Public Assessment Report Swedish 10-04-2018
Patient Information leaflet Patient Information leaflet Norwegian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 15-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 15-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 15-02-2024
Patient Information leaflet Patient Information leaflet Croatian 15-02-2024
Public Assessment Report Public Assessment Report Croatian 10-04-2018

View documents history